847 related articles for article (PubMed ID: 12438245)
21. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor gene expression in human breast cancer biopsy samples: relationship to estrogen and progesterone receptor gene expression.
Dotzlaw H; Miller T; Karvelas J; Murphy LC
Cancer Res; 1990 Jul; 50(14):4204-8. PubMed ID: 2364377
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
24. Expression of estrogen receptors in estrogen receptor-negative human breast carcinoma cells: modulation of epidermal growth factor-receptor (EGF-R) and transforming growth factor alpha (TGF alpha) gene expression.
Sheikh MS; Shao ZM; Chen JC; Li XS; Hussain A; Fontana JA
J Cell Biochem; 1994 Mar; 54(3):289-98. PubMed ID: 8200909
[TBL] [Abstract][Full Text] [Related]
25. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer.
Iwase H; Zhang Z; Omoto Y; Sugiura H; Yamashita H; Toyama T; Iwata H; Kobayashi S
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S34-8. PubMed ID: 12819932
[TBL] [Abstract][Full Text] [Related]
28. Transcriptional control of the ERBB2 amplicon by ERRalpha and PGC-1beta promotes mammary gland tumorigenesis.
Deblois G; Chahrour G; Perry MC; Sylvain-Drolet G; Muller WJ; Giguère V
Cancer Res; 2010 Dec; 70(24):10277-87. PubMed ID: 20961995
[TBL] [Abstract][Full Text] [Related]
29. Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?
Speirs V; Parkes AT; Kerin MJ; Walton DS; Carleton PJ; Fox JN; Atkin SL
Cancer Res; 1999 Feb; 59(3):525-8. PubMed ID: 9973193
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
31. Expression of a repressor of estrogen receptor activity in human breast tumors: relationship to some known prognostic markers.
Simon SL; Parkes A; Leygue E; Dotzlaw H; Snell L; Troup S; Adeyinka A; Watson PH; Murphy LC
Cancer Res; 2000 Jun; 60(11):2796-9. PubMed ID: 10850416
[TBL] [Abstract][Full Text] [Related]
32. Altered gene expression in drug-resistant human breast cancer cells.
Wosikowski K; Schuurhuis D; Kops GJ; Saceda M; Bates SE
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2405-14. PubMed ID: 9815641
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer.
Urban P; Vuaroqueaux V; Labuhn M; Delorenzi M; Wirapati P; Wight E; Senn HJ; Benz C; Eppenberger U; Eppenberger-Castori S
J Clin Oncol; 2006 Sep; 24(26):4245-53. PubMed ID: 16963728
[TBL] [Abstract][Full Text] [Related]
34. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway.
St-Laurent V; Sanchez M; Charbonneau C; Tremblay A
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):23-37. PubMed ID: 15862947
[TBL] [Abstract][Full Text] [Related]
35. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer.
Campbell-Thompson M; Lynch IJ; Bhardwaj B
Cancer Res; 2001 Jan; 61(2):632-40. PubMed ID: 11212261
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers.
Rosa FE; Caldeira JR; Felipes J; Bertonha FB; Quevedo FC; Domingues MA; Moraes Neto FA; Rogatto SR
Hum Pathol; 2008 May; 39(5):720-30. PubMed ID: 18234277
[TBL] [Abstract][Full Text] [Related]
37. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer.
Murphy LC; Hilsenbeck SG; Dotzlaw H; Fuqua SA
Clin Cancer Res; 1995 Feb; 1(2):155-9. PubMed ID: 9815968
[TBL] [Abstract][Full Text] [Related]
38. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
39. Association of ErbB1-4 expression in invasive breast cancer with clinicopathological characteristics and prognosis.
Fujiwara S; Ibusuki M; Yamamoto S; Yamamoto Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):472-81. PubMed ID: 23100016
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
Latil A; Bièche I; Vidaud D; Lidereau R; Berthon P; Cussenot O; Vidaud M
Cancer Res; 2001 Mar; 61(5):1919-26. PubMed ID: 11280747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
